| Current assets: |
| Cash and cash equivalents |
107.65M |
| Short-term investments |
264.26M |
| Contracts receivable |
1.17M |
| Inventories |
5.81M |
| Other current assets |
8.07M |
| Total current assets |
431.83M |
| Property, plant and equipment, net |
89.69M |
| Licenses, net |
6.01M |
| Patents, net |
19.6M |
| Deposits and other assets |
5.82M |
| Total assets |
552.96M |
| Current liabilities: |
| Accounts payable |
5.39M |
| Accrued compensation |
3.82M |
| Accrued liabilities |
17.76M |
| Current portion of long-term obligations |
4.51M |
| Current portion of deferred contract revenue |
35.24M |
| Total current liabilities |
70.3M |
| Long-term deferred contract revenue |
58.82M |
| 2 5/8% convertible subordinated notes |
| Long-term obligations, less current portion |
| Long-term financing liability for leased facility |
70.73M |
| Investment in Regulus Therapeutics Inc. |
| Total liabilities |
351.87M |
| Stockholders' equity: |
| Common stock, $0.001 par value; 200,000,000 shares authorized, 99,618,525 and 99,393,780 shares issued and outstanding at June 30, 2011 and December 31, 2010, respectively |
103K |
| Additional paid-in capital |
1.09B |
| Accumulated other comprehensive income |
17.78M |
| Accumulated deficit |
-908.64M |
| Total stockholders' equity |
| Total liabilities and stockholders' equity |
552.96M |
